90 likes | 243 Views
Colton ellis. Business Model. Lines of Operations Generic Drugs Leading generic pharmaceutical company in the world Innovative Drugs invests in companies with promising products and technologies at the drug discovery phase Teva API (Active Pharmaceutical Ingredients)
E N D
Business Model Lines of Operations • Generic Drugs • Leading generic pharmaceutical company in the world • Innovative Drugs • invests in companies with promising products and technologies at the drug discovery phase • Teva API (Active Pharmaceutical Ingredients) • leading international supplier of active pharmaceutical ingredients
Economic Moat Domination of the market Size and Experience Increasing demand for cheaper prescription drugs
Outlook Greatest risk is the risk of Copaxone patent expiring in 2014. There is an increasing demand for generics. Large amount of R&D to develop new innovative drugs as well as active pharmaceutical ingredients.
Management Acquisitions in key fields R & D spending Patents Returns
Sources Bloomberg Yahoo Finance Morningstar Valueline 10-K Tevapharm.com